{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.6","upperLimit":"85.0","value":"74.6"},{"groupId":"OG001","lowerLimit":"30.1","upperLimit":"62.8","value":"46.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) was defined as the percentage of participants who had achieved a confirmed best overall response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. CR was defined by the disappearance of all non-lymph node target lesions (where all target lesions were recorded with a length of 0 mm, and any pathological lymph nodes \\[recorded as target lesion\\] must have reduction in short axis to \\<10 mm) and complete disappearance of all non-target lesions (where all non-target lesions were marked \"Absent\", and all lymph nodes must be non-pathological in size \\[\\<10 mm in short axis\\]). PR was defined by a 30% or more decrease in sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. ORR was calculated with the exact 2-sided Clopper-Pearson 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-naïve participants with BRAF V600E-mutant metastatic NSCLC were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"OG000","title":"Treatment-Naive"},{"description":"Patients who had received 1) first-line treatment with standard platinum-based chemotherapy, or 2) first-line treatment with an anti-PD-1/PD-L1 inhibitor given alone, or in combination with platinum-based chemotherapy, or in combination with immunotherapy (eg, ipilimumab) with or without platinum-based chemotherapy were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID was to be administered in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"OG001","title":"Previously Treated"}],"paramType":"NUMBER","populationDescription":"Analysis population included all participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)","title":"Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}